Autopsy report · NCT03501979
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
Cause of deathSlow enrollment, also regulatory or ethics
“Study accrual ended early due to the FDA approval of tucatinib in metastatic HER2+ breast cancer”
Life of this trial
- Registered 10 months before it started.
- Ran for about 2 years 4 months before it stopped.
- 17 participants enrolled.
- Results were posted on the registry 1 year 8 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- University of Alabama at Birmingham
- Sponsor type
- University, hospital or other
- Conditions
- Metastatic Breast Cancer; Leptomeningeal Disease
- Interventions
- Tucatinib; Trastuzumab; Capecitabine
- Participants
- 17
- Sites
- 9
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.